Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Zylox-Tonbridge Medical Technology Co., Ltd.
歸創通橋醫療科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2190)

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

References are made to announcements dated August 19, 2025 and October 24, 2025 and the circular of the Company dated October 8, 2025 (the "**Circular**"), in relation to, among others, the mandate (the "**Mandate**") to the Board and/or Administrative Committee to handle matters pertaining to the Share Incentive Scheme. Unless otherwise defined, capitalized terms shall have the same meaning as disclosed in the Circular. This announcement is made by the Company pursuant to Rule 13.51(1) of the Listing Rules.

In view of the fact that the 13.95 million H Shares underlying Awards granted pursuant to the 2025 Share Incentive Scheme have been issued and listed for trading on November 7, 2025, the registered capital of the Company has changed from RMB330,182,001 to RMB344,132,001, and the total share capital has changed from 330,182,001 shares (including 7,781,257 domestic shares and 322,400,744 foreign shares) to 344,132,001 shares (including 7,781,257 domestic shares and 336,350,744 foreign shares).

On December 8, 2025, in order to reflect the aforesaid changes in the registered capital and share capital, the Board resolved to amend the existing articles of association of the Company (the "**Articles of Association**").

The amendments to the existing Articles of Association (the "**Amendments**") are mainly related to the changes in the registered capital and share capital resulting from the issuance of underlying H Shares pursuant to the Share Incentive Scheme. The Board is of the view that the Amendments are in the interests of the Company and the shareholders of the Company (the "**Shareholders**") as a whole.

The details of the Amendments are set out below:

Before Amendment	After Amendment
Article 19 The capital structure of the Company comprises 330,182,001 ordinary shares, including 7,781,257 domestic shares, accounting for 2.36% of the total number of issued ordinary shares of the Company, and 322,400,744 are foreign shares, accounting for 97.64% of the total number of issued ordinary shares of the Company.	**Article 19** The capital structure of the Company comprises **344,132,001** ordinary shares, including 7,781,257 domestic shares, accounting for 2.**2**6% of the total number of issued ordinary shares of the Company, and **336,350,744** are foreign shares, accounting for 97.**7**4% of the total number of issued ordinary shares of the Company.
Article 20 The registered capital of the Company is RMB330,182,001	**Article 20** The registered capital of the Company is RMB**344,132,001.**

Note: The specific details are subject to the approval results of the business registration authority.

Pursuant to the Mandate, the increase in registered capital and the amendments to the Articles of Association do not require the Shareholders' further approval. As confirmed by the Company's PRC legal counsel, the Amendments are administrative in nature and relate solely to the increase in registered capital and share capital resulting from the issuance of underlying H Shares under the Share Incentive Scheme. Accordingly, the Amendments do not require the approval of the Shareholders and have been approved by the Board on December 8, 2025, and have become effective upon such approval.

The full text of the revised Articles of Association has been published on the Company's website (http://www.zyloxtb.com) and the Stock Exchange's website (www.hkexnews.hk).

By order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, December 8, 2025

As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Ms. Yun Qiu and Dr. Xiang Qian as independent non-executive Directors.